Histopathologic Validation of 3′-Deoxy-3′-18F-Fluorothymidine PET in Squamous Cell Carcinoma of the Oral Cavity

被引:18
|
作者
Troost, Esther G. C. [1 ]
Bussink, Johan [1 ]
Slootweg, Piet J. [2 ]
Peeters, Wenny J. M. [1 ]
Merkx, Matthias A. W. [3 ]
van der Kogel, Albert J. [1 ]
Oyen, Wim J. G. [4 ]
Kaanders, Johannes H. A. M. [1 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Inst Oncol, Dept Radiat Oncol, NL-6500 HB Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Inst Oncol, Dept Pathol, NL-6500 HB Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Inst Oncol, Dept Maxillofacial Surg, NL-6500 HB Nijmegen, Netherlands
[4] Radboud Univ Nijmegen, Med Ctr, Inst Oncol, Dept Nucl Med, NL-6500 HB Nijmegen, Netherlands
关键词
F-18-fluorothymidine PET; proliferation; head and neck cancer; immunohistochemistry; iododeoxyuridine; thymidine kinase; CYTOSOLIC THYMIDINE KINASE; F-18-FLT PET; NECK-CANCER; IMAGING PROLIFERATION; NUCLEAR ANTIGEN; IN-VIVO; RADIOTHERAPY; HEAD; REPOPULATION; THERAPY;
D O I
10.2967/jnumed.109.071910
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Accelerated tumor cell repopulation is an important mechanism adversely affecting therapeutic outcome in head and neck cancer. The noninvasive assessment of the proliferative state of a tumor by PET may provide a selection tool for customized treatment. 3'-deoxy-3'-F-18-fluorothymidine (F-18-FLT) is a PET tracer that is phosphorylated by thymidine kinase 1 (TK-1) and, as such, reflects cellular proliferation. Before the use of F-18-FLT PET for tumor characterization is accepted and introduced into clinical studies, validation against tumor histology is mandatory. The aim of this study was to validate F-18-FLT PET in squamous cell carcinomas of the oral cavity using immunohistochemical staining for the proliferation marker iododeoxyuridine and for TK-1. Methods: Seventeen patients with primary squamous cell carcinomas of the oral cavity underwent an F-18-FLT PET/CT scan before surgery, and iododeoxyuridine was administered 20 min before tumor resection. F-18-FLT PET/CT scans were segmented, and PET/CT volumes and PET signal intensities were calculated (mean standardized uptake value [SUVmean] and maximum standardized uptake value [SUVmax]). Multiple paraffin-embedded tumor sections were immunohistochemically stained for iododeoxyuridine and TK-1. For iododeoxyuridine, labeling indices and optical densities were calculated and correlated with SUVmean and SUVmax. TK-1 staining was visually and semiquantitatively assessed. Results: All primary tumors were identified with F-18-FLT PET but with a large range in tracer uptake (mean SUVmax, 5.9; range, 2.2-15.2). Also, there was a large variability in iododeoxyuridine labeling indices (mean, 0.09; range, 0.01-0.29) and optical densities (mean, 28.2; range, 12.6-37.8). The iododeoxyuridine optical densities correlated significantly with SUVmean and SUVmax, but the labeling indices did not. In most tumors, TK-1 staining of varying intensity was present but correlated with neither iododeoxyuridine binding nor F-18-FLT uptake. Conclusion: The current study demonstrated only a weak correlation between F-18-FLT uptake and iododeoxyuridine staining intensity in oral cavity tumors. This weak correlation may be explained by differences in biomarker characteristics, resolution, and quantification methods.
引用
收藏
页码:713 / 719
页数:7
相关论文
共 50 条
  • [1] Histopathologic validation of 3′-deoxy-3′-18F-fluorothymidine PET for detecting tumor repopulation during fractionated radiotherapy of human FaDu squamous cell carcinoma in nude mice
    Yue, Jin-Bo
    Yang, Jia
    Liu, Jing
    Lee, Jason
    Cabrera, Alvin R.
    Sun, Xin-Dong
    Bai, Guang-Hui
    Li, Yu-Hui
    Yu, Jin-Ming
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 (03) : 475 - 481
  • [2] Reproducibility of 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET Tumor Volume Measurements
    Hatt, Mathieu
    Rest, Catherine Cheze-Le
    Aboagye, Eric O.
    Kenny, Laura M.
    Rosso, Lula
    Turkheimer, Federico E.
    Albarghach, Nidal M.
    Metges, Jean-Philippe
    Pradier, Olivier
    Visvikis, Dimitris
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (09) : 1368 - 1376
  • [3] In response to "Histopathologic validation of 3′-deoxy-3′-18F-fluorothymidine PET for detecting tumour repopulation during fractionated radiotherapy in human FaDu squamous cell carcinoma in nude mice"
    Troost, Esther G. C.
    Hoeben, Bianca A. W.
    Laverman, Peter
    Bussink, Jan
    Oyen, Wim J. G.
    RADIOTHERAPY AND ONCOLOGY, 2015, 114 (03) : 417 - 418
  • [4] Usefulness of 3′-Deoxy-3′-18F-Fluorothymidine PET for Predicting Early Response to Chemoradiotherapy in Head and Neck Cancer
    Kishino, Takehito
    Hoshikawa, Hiroshi
    Nishiyama, Yoshihiro
    Yamamoto, Yuka
    Mori, Nozomu
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (10) : 1521 - 1527
  • [5] Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′-18F-fluorothymidine PET
    Waldherr, C
    Mellinghoff, IK
    Tran, C
    Halpern, BS
    Rozengurt, N
    Safaei, A
    Weber, WA
    Stout, D
    Satyamurthy, N
    Barrio, J
    Phelps, ME
    Silverman, DH
    Sawyers, CL
    Czernin, J
    JOURNAL OF NUCLEAR MEDICINE, 2005, 46 (01) : 114 - 120
  • [6] Prognostic value of 3′-Deoxy-3′-18F-Fluorothymidine ([18F] FLT PET) in patients with recurrent malignant gliomas
    Zhao, Fen
    Cui, Yunfeng
    Li, Minghuan
    Fu, Zheng
    Chen, Zhaoqiu
    Kong, Li
    Yang, Guoren
    Yu, Jinming
    NUCLEAR MEDICINE AND BIOLOGY, 2014, 41 (08) : 710 - 715
  • [7] 18F-FDG or 3′-Deoxy-3′-18F-Fluorothymidine to Detect Transformation of Follicular Lymphoma
    Wondergem, Marielle J.
    Rizvi, Saiyada N. F.
    Jauw, Yvonne
    Hoekstra, Otto S.
    Hoetjes, Nikie
    van de Ven, Peter M.
    Boellaard, Ronald
    Chamuleau, Martine E. D.
    Cillessen, Saskia A. G. M.
    Regelink, Josien C.
    Zweegman, Sonja
    Zijlstra, Josee M.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (02) : 216 - 221
  • [8] 3′-Deoxy-3′-[18F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer
    Chen, Haojun
    Li, Yimin
    Wu, Hua
    Sun, Long
    Lin, Qin
    Zhao, Long
    An, Hanxiang
    STRAHLENTHERAPIE UND ONKOLOGIE, 2015, 191 (02) : 141 - 152
  • [9] A Pilot Study to Evaluate 3′-Deoxy-3′-18F-Fluorothymidine PET for Initial and Early Response Imaging in Mantle Cell Lymphoma
    Herrmann, Ken
    Buck, Andreas K.
    Schuster, Tibor
    Rudelius, Martina
    Wester, Hans-Juergen
    Graf, Nicolas
    Scheuerer, Christine
    Peschel, Christian
    Schwaiger, Markus
    Dechow, Tobias
    Keller, Ulrich
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (12) : 1898 - 1902
  • [10] Early Determination of Prognosis by Interim 3′-Deoxy-3′-18F-Fluorothymidine PET in Patients with Non-Hodgkin Lymphoma
    Lee, Hyewon
    Kim, Seok-ki
    Kim, Yong-Il
    Kim, Tae Sung
    Kang, Se Hun
    Park, Weon Seo
    Yun, Tak
    Eom, Hyeon-Seok
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (02) : 216 - 222